Menarini And Radius Skip Into SERD Lead With Elacestrant Success
Breast Cancer Therapy Improves PFS In Phase III EMERALD Trial
Elacestrant has become the first oral SERD to generate positive topline results in a pivotal study as a monotherapy versus standard of care for ER+/HER2- advanced or metastatic breast cancer.
